This is the mp3 version. From episode 30 onward this is the same as the AAC version. Prior to that, the AAC version had chapter markings.
Visit https://TalkingAboutGlaucoma.com to BuyMeACoffee, find all my social feeds, subscribe to the newsletter, provide feedback and Register as a Guest if you want to be on a future episode.
More information about Dr Gavin Docherty can be found at https://www.talkingaboutglaucoma.com/guests/gavin/
Theme music “Middle East Gold” ©Daniel Schertzer 2010 and published by Les Prods DOSWA Enr
This episode ©Dr Robert Schertzer Inc 2024
Visit https://TalkingAboutGlaucoma.com to find all my social feeds, subscribe to the newsletter, provide feedback and Register as a Guest if you want to be on a future episode.
More information about Dr Mahnia Madan can be found at https://www.talkingaboutglaucoma.com/guests/mahnia-madan/
This episode has been sponsored by Sun Pharma Canada Inc., which did not provide any material or exercise editorial control over the content.
In this episode, I talk with Abdullah “Abed” Sarhan, CEO and Co-founder of Retinal Logic, about the company's use of AR and VR technology for vision screening. Abbott shares his background in deep learning and healthcare, the development of the virtual reality prototype, the device's availability and Health Canada approval, and its differentiation from other companies' technologies. He also discusses the various test sizes and algorithms available, ongoing research, user experience, and the company's future roadmap.
Visit https://TalkingAboutGlaucoma.com to find all my social feeds, subscribe to the newsletter, provide feedback and Register as a Guest if you want to be on a future episode.
About Abbott Sarhan and selected references can be found at: https://www.talkingaboutglaucoma.com/guests/abdullah-sarhan/
In this episode, I go beyond the basics of Optical Coherence Tomography (OCT) with Dr Hady Saheb from McGill University. Our discussion includes Ganglion Cell Layer analysis, structure-function correlation, the floor effect, viewing-software vs printouts and explaining test results to patients.
Visit https://TalkingAboutGlaucoma.com to find all my social feeds, subscribe to the newsletter, provide feedback and Register as a Guest if you want to be on a future episode.
About Hady Saheb and selected references:https://www.talkingaboutglaucoma.com/guests/hady-saheb/
Intro:
In this episode, I discuss Plateau Iris with Dr Shivani Kamat, Assistant Professor of Ophthalmology and Glaucoma Fellowship Program director at UT Southwestern. She also founded and co-chairs Women in Glaucoma. Today's discussion includes the difference between plateau iris configuration and syndrome, how to distinguish it from other glaucomas and treatment options.
Outro:
Talking About Glaucoma is a podcast of indeterminate frequency and duration...recently averaging 4 episodes per year. I'm still hoping to get this out monthly in the future. It’s free on Apple Podcasts, Spotify, Google Podcasts, PocketCasts, Podcast Addict, and many other podcast services. Please rate the podcast on your podcast player of choice, subscribe to it, and tell your friends about it so that it can reach more listeners and encourage me to continue to produce new episodes. Follow me at WestCoastGlaucoma on Instagram and Talking About Glaucoma on Facebook. Drop me a line at podcast@iguy.org with your show ideas, if you would like to be on a future episode or questions you would like to have answered on future episodes. Keep informed to prevent needless loss of vision from glaucoma. See you next time on Talking About Glaucoma.
About Shivani Kamat (taken from the UT Southwestern Medical Centre website):
Shivani Kamat, M.D., is an Assistant Professor in the Department of Ophthalmology and Director of the Glaucoma Fellowship at UT Southwestern Medical Center. She specializes in complex glaucoma, anterior segment disease, minimally invasive glaucoma surgery, and cataract surgery and has extensive experience in medical, laser, and surgical treatment of glaucoma, including combined cataract and glaucoma procedures as well as the latest glaucoma surgical devices and intraocular lens implant technology.
Dr. Kamat earned her medical degree at the University of Florida in Gainesville. She completed an internship in internal medicine at the UF Health Shands Hospital, a residency in ophthalmology at Loyola University, and a fellowship in glaucoma at Massachusetts Eye and Ear, a primary teaching hospital of Harvard Medical School.
Certified by the American Board of Ophthalmology, she joined the UT Southwestern faculty in 2022. Previously, she was an Assistant Professor at the University of Michigan Kellogg Eye Center in Ann Arbor, where she served as the Glaucoma Fellowship Director and the Medical Director of the center’s community clinic in Brighton, Michigan.
Dr. Kamat founded and co-chairs Women in Glaucoma. She serves on multiple committees of the American Glaucoma Society and as an examiner for the American Board of Ophthalmology. She is also a member of the American Academy of Ophthalmology, the American Society of Cataract and Refractive Surgery, and the Dallas Academy of Ophthalmology.
Dr. Kamat is actively involved in clinical research; her interests include the epidemiology of glaucoma, minimally invasive glaucoma surgery, anterior segment disease, and plateau iris syndrome. She has lectured widely and published numerous research articles on these and related topics in publications such as Nature, Ophthalmology, JAMA Ophthalmology, Journal of Glaucoma, and EyeNet Magazine. In addition, she has served as a reviewer for the Journal of Glaucoma, contributed to a book on gonioscopy-assisted transluminal trabeculotomy, and been interviewed for stories in national magazines and digital platforms.
Selected references:
Shivani S Kamat, Helen L Kornmann, Kugler Publications. GATT in Secondary Glaucoma in GATT: Gonioscopy Assisted Transluminal Trabeculotomy- A Guide to Circumnavigating Schlemm's Canal from Around the World
SS Kamat, MS Gregory, LR Pasquale - Seminars in ophthalmology, 2016 - Taylor & Francis. The role of the immune system in glaucoma: bridging the divide between immune mechanisms in experimental glaucoma and the human disease
JR Ehrlich, AR Elam, D John, SS Kamat… - JAMA …, 2020 - jamanetwork.com Application of the sight outcomes research collaborative ophthalmology data repository for triaging patients with glaucoma and clinic appointments during pandemics
SJ Garnai, LA Huryn, K Johnson, SS Kamat… - Scientific reports, 2020 - nature.com Novel TMEM98, MFRP, PRSS56 variants in a large United States high hyperopia and nanophthalmos cohort
M Rahman, C Andrews, JR Ehrlich, S Kamat… - JAMA …, 2019 - jamanetwork.com Evaluation of an algorithm for identifying ocular conditions in electronic health record data
WS Lieb, G Fabry, KN Allen, SS Kamat… - … & Visual Science, 2017 - arvojournals.org The ability of nitric oxide to lower intraocular pressure is dependent on guanylyl cyclase
JA Musser, LM Niziol, MM Heisler, SS Kamat… - Journal of …, 2019 - ncbi.nlm.nih.gov Integrating patient education into the glaucoma clinical encounter: a lean analysis
MM Shah, AR Elam, SS Kamat… - Clinical …, 2020 - Taylor & Francis The appropriateness of digital diabetic retinopathy screening images for a computer-aided glaucoma screening system
Production information:
This episode was recorded back on April 22, 2022 over Zoom. Mixing was finally completed March 20, 2023 using Hindenberg Journalist Pro software iZotope processing plug-ins on a Gigabyte AERO 17 computer. The narration was overdubbed using a Heil PR40 microphone through an SSL 2 USB Audio.
The opinions expressed in this podcast are those of the speakers and are not intended to be taken as the standard of care for glaucoma treatment. Please always weigh the complete clinical picture and involve patients with any decisions in their care.
Robert M Schertzer, MD, MEd, FRCSC
podcast@iguy.org
Twitter - https://twitter.com/robschertzer
or http://iguy.tv/twitter
Blog - http://wholelottarob.com
or http://iguy.tv/blog
Facebook - https://facebook.com/talkingaboutglaucoma
Office website - https://westcoastglaucoma.com
or http://iguy.tv/office
YouTube channel - https://youtube.com/robschertzer
Instagram - https://instagram.com/westcoastglaucoma
Theme music “Middle East Gold” ©Daniel Schertzer 2010 and published by Les Prods DOSWA Enr
© 2023 DOSWA Prods Enr/Robert M Schertzer MD. MEd, FRCSC
iTunes Subtitle:
A discussion with Shivani Kamat about Plateau Iris. The discussion includes the difference between plateau iris configuration and syndrome, how to distinguish plateau iris from other glaucoma and its implication for treatment options.
iTunes Summary:
In this episode, I talk with Dr Shivani Kamat, Associate Professor of Ophthalmology and Glaucoma Fellowship Program director at UT Southwestern, about Plateau Iris. The discussion includes the difference between plateau iris configuration and syndrome, how to distinguish plateau iris from other glaucoma and its implication for treatment options.
SEO Title
Discussion with Shivani Kamat about Plateau Iris
SEO Description
The discussion includes the difference between plateau iris configuration and syndrome, how to distinguish plateau iris from other glaucoma and its implication for treatment options.
iTunes TAG 37
Intro:
In this episode, I talk with Carla Siegfried, Jacquelyn E. and Allan E. Kolker, MD Distinguished Professor of Ophthalmology and Vice-Chair of Diversity, Equity, and Professionalism at Washington University School of Medicine, about the gold standard glaucoma surgical procedure: the trabeculectomy. We exchange detailed tips for success for each step of the surgery and post-operative care. It is clear from our discussion that we must continue to train others so that the trabeculectomy does not become a lost art. This is a procedure requiring no special devices and remains the gold standard for achieving low pressures despite its higher complication rate compared to other procedures.
There are some audio issues with the recording of this episode that I've cleaned up as best I can. I'm Rob Schertzer, a Vancouver, Canada-based glaucoma specialist, podcaster and HealthIT expert, and we're...talking about glaucoma.
Outro:
Talking About Glaucoma is a podcast of indeterminate frequency and duration...recently averaging 4 episodes per year. I'm still hoping to get this out monthly in the future. It’s available for free on Apple Podcasts, Spotify, Google Podcasts, PocketCasts, Podcast Addict, and many other podcast services. Please rate the podcast on your podcast player of choice, subscribe to it, and tell your friends about it, so that it can reach more listeners and encourage me to continue to produce new episodes. Follow me at WestCoastGlaucoma on Instagram and Talking About Glaucoma on Facebook. Drop me a line at podcast@iguy.org with your show ideas, if you would like to be on a future episode or questions you would like to have answered on future episodes. Keep informed to prevent needless loss of vision from glaucoma. See you next time on Talking About Glaucoma.
About Carla Siegfried:
Carla J. Siegfried, MD
Jacquelyn E. and Allan E. Kolker, MD Distinguished Professor of Ophthalmology
Vice Chair of Diversity, Equity, and Professionalism
John F. Hardesty, MD Department of Ophthalmology and Visual Sciences
Washington University School of Medicine
660 South Euclid Ave.
MSC-8096-05-721
St. Louis, MO 63110
314-362-3937
siegfried@wustl.edu
Selected references from past 5 years:
1: Ban N, Siegfried CJ, Apte RS. Monitoring Neurodegeneration in Glaucoma:
Therapeutic Implications. Trends Mol Med. 2018 Jan;24(1):7-17. doi:
10.1016/j.molmed.2017.11.004. Epub 2017 Dec 7. PMID: 29233479; PMCID:
PMC5748344.
2: Siegfried CJ. Setting the Gold(en) Standard for Ethical Care:
10.1016/j.ophtha.2018.09.011. Epub 2018 Sep 19. PMID: 30240792.
3: Van Gelder RN, Siegfried CJ. ROI, COI, and the Ethical Obligations of
Journals. Ophthalmology. 2022 Jun;129(6):602-604. doi:
10.1016/j.ophtha.2022.04.007. PMID: 35598900.
4: De Maria A, Zientek KD, David LL, Wilmarth PA, Bhorade AM, Harocopos GJ,
Huang AJW, Hong AR, Siegfried CJ, Tsai LM, Sheybani A, Bassnett S. Compositional
Analysis of Extracellular Aggregates in the Eyes of Patients With Exfoliation
Syndrome and Exfoliation Glaucoma. Invest Ophthalmol Vis Sci. 2021 Dec
1;62(15):27. doi: 10.1167/iovs.62.15.27. PMID: 34964803; PMCID: PMC8740535.
5: Pelton RW, Siegfried CJ. Re: Bartley: Verifying surgical competence: our
fiduciary responsibility (Ophthalmology. 2020;127:997-999). Ophthalmology. 2020
Dec;127(12):e111-e112. doi: 10.1016/j.ophtha.2020.06.022. Epub 2020 Jul 29.
PMID: 32739188.
6: Siegfried CJ, Shui YB. Intraocular Oxygen and Antioxidant Status: New
Insights on the Effect of Vitrectomy and Glaucoma Pathogenesis. Am J Ophthalmol.
2019 Jul;203:12-25. doi: 10.1016/j.ajo.2019.02.008. Epub 2019 Feb 15. PMID:
30772349; PMCID: PMC6612589.
7: Siegfried CJ, Shui YB, Tian B, Nork TM, Heatley GA, Kaufman PL. Effects of
Vitrectomy and Lensectomy on Older Rhesus Macaques: Oxygen Distribution,
Antioxidant Status, and Aqueous Humor Dynamics. Invest Ophthalmol Vis Sci. 2017
Aug 1;58(10):4003-4014. doi: 10.1167/iovs.17-21890. PMID: 28800647; PMCID:
PMC5555251.
—————————————————————————
Production information:
This episode was recorded February 29, 2020 during the Annual Meeting of the American Glaucoma Society in Washington, DC, unfortunately using a BOYA Dual Lapel USB-C Microphone BY-M3D - which I do not recommend. Mixing was finally completed to salvage the recording on May 9, 2022 using Hindenberg Journalist Pro software iZotope processing plug-ins on a Gigabyte AERO 17 computer. The narration was overdubbed using a Heil PR40 microphone through an SSL 2 USB Audio Interface onJune 6, 2022.
The opinions expressed in this podcast are those of the speakers and are not intended to be taken as the standard of care for glaucoma treatment. Please always weigh the complete clinical picture and involve patients with any decisions in their care.
Robert M Schertzer, MD, MEd, FRCSC
podcast@iguy.org
Twitter - https://twitter.com/robschertzer
or http://iguy.tv/twitter
Blog - http://wholelottarob.com
or http://iguy.tv/blog
Facebook - https://facebook.com/talkingaboutglaucoma
Office website - https://westcoastglaucoma.com
or http://iguy.tv/office
YouTube channel - https://youtube.com/robschertzer
Instagram - https://instagram.com/westcoastglaucoma
Theme music “Middle East Gold” ©Daniel Schertzer 2010 and published by Les Prods DOSWA Enr
© 2022 DOSWA Prods Enr/Robert M Schertzer MD. MEd, FRCSC
TAG #35 GEDDE Steve - Glaucoma surgical trials: lessons learned
Intro:
There have been many trials proving surgical intervention does indeed reduce the risk of progressive glaucoma damage for our patients. These include Treatment vs No Treatment studies as well as studies that compare different types of treatment. In this episode, I talk with Steve Gedde, from the University of Miami's Bascom Palmer Eye Institute, about lessons learned from these clinical trials.
We begin by discussing the importance of Randomized Clinical Trials as the highest evidence-based medicine to compare treatments.
Studies that we discuss include: the Fluorouracil Filtering Study Group; Tube vs Trab (TVT); Primary Tube vs Trab (PTVT); Ahmed Baervedlt Comparison (ABC); Ahmed vs Baerveldt.
Some of the concepts and lessons learned include: reducing IOP prior to surgery to lessen the risk of choroidal hemorrhage from a sudden IOP drop; trabeculectomy offering titratable control that MIGS procedures do not; that it's harder to get a 20% reduction in IOP to count as a success if the IOP is lower than 25 pre-op; that Ahmed Valves have a better safety record but Baerveldt better pressure-lowering; and that antimetabolites have been shown to NOT be effective for tube-shunt surgery.
There's quite a bit of information packed into this episode so I suggest checking the program notes for links to some relevant articles and presentations related to this topic.
I'm Rob Schertzer, a Vancouver, Canada based glaucoma specialist, podcaster and HealthIT expert, and we're...talking about glaucoma.
Outro:
Talking About Glaucoma is a podcast of indeterminate frequency and duration. It’s available for free on Apple Podcasts, Spotify, Google Podcasts, PocketCasts, and many other podcast services. Please rate the podcast on Apple Podcasts, subscribe to it, and tell your friends about it, so that it can reach more listeners and encourage me to continue to produce new episodes. Follow WestCoastGlaucoma on Instagram and Talking About Glaucoma on Facebook. Drop me a line at podcast@iguy.org with your show ideas or questions you would like to have answered on future episodes. Keep informed to prevent needless loss of vision from glaucoma. See you next time on Talking About Glaucoma.
I'm Rob Schertzer, a Vancouver-based Glaucoma specialist, EMR guru and tech geek and we're...talking about glaucoma.
About Steve Gedde:
https://doctors.umiamihealth.org/provider/Steven+J+Gedde/524953
Professor of Ophthalmology
John G. Clarkson Chair in Ophthalmology
Vice Chair of Education and Residency Program Director
Selected references:
This link may have restricted access to American Glaucoma Society members. It is a lecture that Dr. Gedde delivered at the March 2020 AGS Annual Meeting in Washington DC entitled: Lessons Learned from Glaucoma Surgical Trials
https://www.aao.org/annual-meeting-video/lessons-learned-from-glaucoma-surgical-trials
Here is a reasonably comprehensive list of glaucoma clinical trials, broken down as Treatment vs No Treatment and Treatment vs Treatment
https://eyewiki.aao.org/Clinical_Trials_in_Glaucoma
—————————————————————————
Production information:
This episode was recorded February 29, 2020 during the Annual Meeting of the American Glaucoma Society in Washington, DC, unfortunately using a BOYA Dual Lapel USB-C Microphone BY-M3D - which I do not recommend. Mixing and sound levelling were finally completed to salvage the recording on February 21, 2022 using Hindenberg Journalist Pro software iZotope processing plug-ins on a Gigabyte AERO 17 computer. The narration was overdubbed using a Heil PR40 microphone.
Opinions expressed in this podcast are those of the speakers and are not intended to be taken as the standard of care for glaucoma treatment. Please always weigh the complete clinical picture and involve patients with any decisions in their care.
Robert M Schertzer, MD, MEd, FRCSC
podcast@iguy.org
Twitter - https://twitter.com/robschertzer
or http://iguy.tv/twitter
Blog - http://wholelottarob.com
or http://iguy.tv/blog
Facebook - https://facebook.com/talkingaboutglaucoma
Office website - https://westcoastglaucoma.com
or http://iguy.tv/office
YouTube channel - https://youtube.com/robschertzer
Instagram - https://instagram.com/westcoastglaucoma
Theme music “Middle East Gold” ©Daniel Schertzer 2010 and published by Les Prods DOSWA Enr
© 2022 DOSWA Prods Enr/Robert M Schertzer MD. MEd, FRCSC
—————————————————————————
iTunes Subtitle:
A talk with Steve Gedde on lessons learned from glaucoma surgery randomized controlled trials.
iTunes Summary:
In this episode, I talk with Steve Gedde, from the University of Miami's Bascom Palmer Eye Institute, about lessons learned from these clinical trials.
We begin by discussing the importance of Randomized Clinical Trials as the highest evidence-based medicine to compare treatments. Studies that we discuss include: the Fluorouracil Filtering Study Group; Tube vs Trab (TVT); Primary Tube vs Trab (PTVT); Ahmed Baervedlt Comparison (ABC); Ahmed vs Baerveldt.
Some of the concepts and lessons learned include: reducing IOP prior to surgery to lessen the risk of choroidal hemorrhage from a sudden IOP drop; trabeculectomy offering titratable control that MIGS procedures do not; that it's harder to get a 20% reduction in IOP to count as a success if the IOP is lower than 25 pre-op; that Ahmed Valves have a better safety record but Baerveldt better pressure-lowering; and that antimetabolites have been shown to not be effective for tube-shunt surgery.
Intro: Welcome to Talking About Glaucoma episode #34 for May 7, 2021. Here’s another recording from the vaults that is getting to see the light of day. It is one of 3 episodes recorded in person back in late February 2020 just before Covid de-railed us all from business as usual. My apologies for the sound quality on this one; I was experimenting with a BOYA dual lapel mic, recording directly into my phone: big mistake! Future recordings from episode 37 onward will go back to my professional recording gear.
Email me at podcast@iguy.org if you would like to be on the show to discuss a topic in glaucoma or if you have questions that you would like to have answered on a future episode. Check out WestCoastGlaucoma on Instagram https://instagram.com/westcoastglaucoma for some short-form videos that can also be found on my robschertzer YouTube channel. https://youtube.com/robschertzer where your subscription will help improve future content.
In this episode, I talk with Daniel Laroche. We have crossed paths for many years at conferences having both started our practices at the same time, but this was the first time we sat down to record our conversation. Daniel Laroche is Director of Glaucoma Services and President of Advanced Eyecare of New York. He is affiliated with the New York Eye and Ear Infirmary, and Assistant Professor of Ophthalmology at the Mount Sinai School of Medicine, New York. I'm Rob Schertzer, a Vancouver, Canada based glaucoma specialist, podcaster and HealthIT expert, and we're...talking about glaucoma.
Outro:
That’s our show for today! Talking About Glaucoma is a podcast of indeterminate frequency and duration. It’s available for free on Apple Podcasts, Spotify, Google Podcasts, PocketCasts, and wherever fine podcasts are curated. Please rate the podcast on Apple Podcasts, subscribe to it, and tell your friends about it, so that it can reach more listeners. Follow me at WestCoastGlaucoma on Instagram, Talking About Glaucoma on Facebook and robschertzer on YouTube. Drop me a line at podcast@iguy.org with your show ideas or questions you would like to have answered on future episodes. Keep informed to prevent needless loss of vision from glaucoma, stay safe, wear a mask and get vaccinated. See you next time on Talking About Glaucoma.
—————————————————————————
About our guest
Daniel Laroche is Director of Glaucoma Services and President of Advanced Eyecare of New York (https://www.advancedeyecareny.com). He is affiliated with the New York Eye and Ear Infirmary, and Assistant Professor of Ophthalmology at the Mount Sinai School of Medicine, New York (https://www.mountsinai.org/profiles/daniel-laroche2).
YouTube videos
Ciliary Body Suprachoroidal Microtube https://youtu.be/34WPtWZ7SeE
Combined Goniotomy and SC Microtobue https://youtu.be/IVe95AvBHfA
Publications by Daniel Laroche:
Real World Outcomes of Kahook Dual Blade Goniotomy in Black and Afro-Latinx Adult Patients with Glaucoma: A 6-Month Retrospective Study
The Aging Lens and Glaucoma in persons over 50: Why early cataract surgery/refractive lensectomy and microinvasive trabecular bypass can prevent blindness and cure elevated eye pressure
Combination microinvasive glaucoma surgery: 23-gauge cystotome goniotomy and intra-scleral ciliary sulcus suprachoroidal microtube surgery in refractory and severe glaucoma: A case series
Clear Lensectomy, Goniosynechiolysis and Hydrus Microstent in a Patient with Mixed Mechanism Glaucoma
Preserving vision in the COVID-19 pandemic: Focus on health equity
Combined microinvasive glaucoma surgery in osteogenesis imperfecta patient with refractory open angle glaucoma
Real-world retrospective consecutive study of ab interno XEN 45 gel stent implant with mitomycin C in black and afro-latino patients with glaucoma: 40% required secondary glaucoma surgery at 1 year
Intra-Scleral Ciliary Sulcus Suprachoroidal Microtube: Making Supraciliary Glaucoma Surgery Affordable
A Novel Low Cost Effective Technique in Using a 23 Gauge Straight Cystotome to Perform Goniotomy: Making Micro-invasive Glaucoma Surgery (MIGS) Accessible to the Africans and the Diaspora
A novel use of trypan blue during canalicular glaucoma surgery to identify aqueous outflow to episcleral and intrascleral veins
—————————————————————————
Production information:
This episode was recorded February 28, 2020 during the Annual Meeting of the American Glaucoma Society in Washington, DC. In a first for me, I recorded direct to a Huawei Mate20 Pro running Easy Voice Recorder Pro using a BOYA BY-M3D dual lapel microphone. As you will hear, this was a mistake but unfortunately I used this same recording setup for the next two episodes as well. After that, I’ll go back to my Shure SM58 microphones and Marantz recorder! Mixing and sound levelling were finally completed May 5, 2021 on an M1 MacMini using Hindenberg Journalist Pro software and Flux Software sound processing. Narration was overdubbed using a HEIL PR40 microphone.
Opinions expressed in this podcast are those of the speakers and are not intended to be taken as the standard of care for glaucoma treatment. Please always weigh the complete clinical picture and involve patients with any decisions in their care.
Robert M Schertzer, MD, MEd, FRCSC
podcast@iguy.org
Twitter - https://twitter.com/robschertzer
or http://iguy.tv/twitter
Blog - http://wholelottarob.com
or http://iguy.tv/blog
Facebook - https://facebook.com/talkingaboutglaucoma
Office website - https://westcoastglaucoma.com
or http://iguy.tv/office
YouTube channel - https://youtube.com/robschertzer
Instagram - https://instagram.com/westcoastglaucoma
Theme music “Middle East Gold” ©Daniel Schertzer 2010 and published by Les Prods DOSWA Enr
© 2021 DOSWA Prods Enr/Robert M Schertzer MD. MEd, FRCSC
—————————————————————————
Intro: Welcome to Talking About Glaucoma episode #33 for December 31, 2020. I bet you're glad this year is over! I'm still digging through the vaults to post episodes like this gem and have a few more that will go live soon. Email me at podcast@iguy.org if you would like to be on the show to discuss a topic in glaucoma or if you have questions that you would like to have answered on a future episode. Check out WestCoastGlaucoma on Instagram https://instagram.com/westcoastglaucoma for some short-form videos that can also be found on my robschertzer YouTube channel. https://youtube.com/robschertzer.
In this episode, I talk with Gus DeMoraes, a frequent guest of the pod. Gus is Associate Professor of Ophthalmology at Columbia University where he serves as Medical Director of Clinical Trials. When we originally sat down to record this way back in March 2019, he had just presented some of the work he had done in collaboration with Don Hood. This has now appeared on Humphrey perimeters as the 24-2C testing strategy and is becoming a new the standard of care. It is based on reports in recent years that glaucoma damage often occurs in the macular area but missed because the standard 24-2 testing strategy only tests in 6 degree increments. These early central glaucomatous defects are often hidden between the test points. Listen in as I talk with Gus.
I'm Rob Schertzer, a Vancouver, Canada based glaucoma specialist, podcaster and HealthIT expert, and we're...talking about glaucoma.
Outro: Talking About Glaucoma is a podcast of indeterminate frequency and duration. It’s available for free on Apple Podcasts, Spotify, Google Podcasts, PocketCasts, and many other podcast services. Please rate the podcast on Apple Podcasts, subscribe to it, and tell your friends about it, so that it can reach more listeners. Follow WestCoastGlaucoma on Instagram and Talking About Glaucoma on Facebook. Drop me a line at podcast@iguy.org with your show ideas or questions you would like to have answered on future episodes. Keep informed to prevent needless loss of vision from glaucoma, stay safe, wear a mask and get vaccinated. See you next time on Talking About Glaucoma.
—————————————————————————
About our guest:
Gus DeMoraes: https://www.columbiaeye.org/profile/cgdemoraes?profile=researcher
Relevant publications
DE MORAES CG, Sun A, Jarukasetphon R, Rajshekhar R, Shi L, Blumberg DM, Liebmann JM, Ritch R, Hood DC. Association of Macular Visual Field Measurements With Glaucoma Staging Systems. JAMA Ophthalmol. 2018 Nov 8 [Epub ahead of print]
Mavrommatis MA, Wu Z, Naegele SI, Nunez J, DE MORAES CG, Ritch R, Hood DC. Deep Defects Seen on Visual Fields Spatially Correspond Well to Loss of Retinal Nerve Fiber Layer Seen on Circumpapillary OCT Scans. Invest Ophthalmol Vis Sci. 2018;59(2):621-628
Garg A, DE MORAES CG, Cioffi GA, Girkin CA, Medeiros FA, Weinreb RN, Zangwill L, Liebmann JM. Baseline 24-2 Central Visual Field Damage is Predictive of Global Progressive Field Loss. Am J Ophthalmol. 2018;187:92-98
—————————————————————————
Production information:
This episode was recorded March 17, 2019 during the Annual Meeting of the American Glaucoma Society in San Francisco using two Shure SM58 microphones with a Marantz PMD661 digital recorder. Mixing and sound levelling were finally completed December 30, 2020 on an HP Spectre x360 laptop using Hindenberg Journalist Pro software and Flux Software sound processing. Narration was overdubbed using an Audio-Technica ATR2100-USB.
Opinions expressed in this podcast are those of the speakers and are not intended to be taken as the standard of care for glaucoma treatment. Please always weigh the complete clinical picture and involve patients with any decisions in their care.
Robert M Schertzer, MD, MEd, FRCSC
podcast@iguy.org
Twitter - https://twitter.com/robschertzer
or http://iguy.tv/twitter
Blog - http://wholelottarob.com
or http://iguy.tv/blog
Facebook - https://facebook.com/talkingaboutglaucoma
Office website - https://westcoastglaucoma.com
or http://iguy.tv/office
YouTube channel - https://youtube.com/robschertzer
Instagram - https://instagram.com/westcoastglaucoma
Theme music “Middle East Gold” ©Daniel Schertzer 2010 and published by Les Prods DOSWA Enr
© 2020 DOSWA Prods Enr/Robert M Schertzer MD. MEd, FRCSC
—————————————————————————
iTunes Subtitle:
A talk with Gus DeMoraes on the development of the Humphrey 24-2C testing strategy.
iTunes Summary:
In this episode, I talk with Gus DeMoraes, a frequent guest of the pod. Gus is Associate Professor of Ophthalmology at Columbia University where he serves as Medical Director of Clinical Trials. When we originally sat down to record this way back in March 2019, he had just presented some of the work he had done in collaboration with Don Hood. This has now appeared on Humphrey perimeters as the 24-2C testing strategy and is becoming a new the standard of care. It is based on reports in recent years that glaucoma damage often occurs in the macular area but missed because the standard 24-2 testing strategy only tests in 6 degree increments. These early central glaucomatous defects are often hidden between the test points.
I'm Rob Schertzer, a Vancouver, Canada based glaucoma specialist, podcaster and HealthIT expert, and we're...talking about glaucoma.
Intro:
My apologies for the >1 year gap since my last episode. It's been quite the year moving my work back to full time in Vancouver and providing patient care in our new normal of a pandemic. There are many more episodes that have been recorded; I'll keep trying to get them posted more often. Email me at podcast@iguy.org if you would like to be on the show.
In this episode, I talk with Won Kim, a glaucoma colleague based at Walter Reed National Military Medical Center and Hospital in Bethesda, Maryland, about why he has been combining multiple minimally invasive glaucoma procedures in patients who have failed traditional glaucoma surgery. I'm Rob Schertzer, a Vancouver, Canada based glaucoma specialist, podcaster and HealthIT expert, and we're...talking about glaucoma.
Outro:
Talking About Glaucoma is a podcast of indeterminate frequency and duration. It’s available for free on Apple Podcasts, Spotify, Google Podcasts, PocketCasts, and many other podcast services. Please rate the podcast on Apple Podcasts and tell your friends about it, so that it can reach more listeners. Drop me a line at podcast@iguy.org with your show ideas.
—————————————————————————
Production information:
This episode was recorded March 16, 2019 during the Annual Meeting of the American Glaucoma Society in San Francisco using two Shure SM58 microphones with a Marantz PMD661 digital recorder. Mixing and sound levelling were finally completed September 9, 2020 on a home brewed Windows X computer using Hindenberg Journalist Pro software and Flux Audio plug-ins. Narration was overdubbed using a Blue Yeti Microphone.
Opinions expressed in this podcast are those of the speakers and are not intended to be taken as the standard of care for glaucoma treatment. Please always weigh the complete clinical picture and involve patients with any decisions in their care.
Robert M Schertzer, MD, MEd, FRCSC
podcast@iguy.org
Twitter - http://twitter.com/robschertzer or http://iguy.tv/twitter
Blog - http://wholelottarob.com or http://iguy.tv/blog
Facebook - http://facebook.com/talkingaboutglaucoma
Office website - http://westcoastglaucoma.com
or http://iguy.tv/office
Theme music “Middle East Gold” ©Daniel Schertzer 2010 and published by Les Prods DOSWA Enr
© 2020 DOSWA Prods Enr/Robert M Schertzer MD. MEd, FRCSC
—————————————————————————
Today’s guest:
Won I. Kim, MD
MD: George Washington University School of Medicine
Ophthalmology Residency: San Antonio Uniformed Services Health Education Consortium
Glaucoma Fellowship: Bascom Palmer Eye Institute
Current: Program Director, Walter Reed National Military Medical Center, National Capital Consortium Ophthalmology Residency
wonkim74@hotmail.com
—————————————————————————
iTunes Subtitle:
A talk with Won I. Kim, a staff Ophthalmologist and Glaucoma Specialist at Walter Reed in Bethesda, MD, discussing combined minimally invasive glaucoma surgeries as an option for treatment of glaucoma that has failed traditional surgeries.
iTunes Summary:
In this episode, I talk with Won Kim, a glaucoma colleague based on Walter Reed in Bethesda, Maryland, about how he has been combining multiple minimally invasive glaucoma procedures in patients who have failed traditional glaucoma surgery. I'm Rob Schertzer, a Vancouver, Canada based glaucoma specialist, podcaster and HealthIT expert, and we're...talking about glaucoma.
The goal of the late Dave Epstein was to find a drug that treats the cause of glaucoma by improving trabecular meshwork outflow. After many years of research, Aerie Pharmaceuticals was formed and refined a Rho Kinase inhibitor called Netarsudil. In April 2018 this came to market as Rhopressa and March 2019, combined with latanoprost, as Roclatan. Today I’m talking with Rick Lewis, a glaucoma colleague based in Sacramento and Chief Medical Officer for Aerie Pharmaceuticals…and we’re Talking About Glaucoma.
Talking About Glaucoma is a podcast of indeterminate frequency and duration. It’s available for free on Apple Podcasts, Google Podcasts, PocketCasts, and many other podcast services. Please rate the podcast on Apple Podcasts and tell your friends about it, so that it can reach more listeners. Drop me a line at podcast@iguy.org with your show ideas.
—————————————————————————
Selected links:
https://aeriepharma.com/
https://clinicaltrials.gov/ct2/show/NCT02246764
—————————————————————————
Production information:
This episode was recorded March 2019 during the Annual Meeting of the American Glaucoma Society in San Francisco using two Shure SM58 microphones with a Marantz PMD661 digital recorder. Mixing and sound levelling were completed June 2019 on an iMac using Hindenberg Journalist Pro software. Narration was overdubbed using a Blue Yeti Microphone.
Opinions expressed in this podcast are those of the speakers and are not intended to be taken as the standard of care for glaucoma treatment. Please always weigh the complete clinical picture and involve patients with any decisions in their care.
Robert M Schertzer, MD, MEd, FRCSC
podcast@iguy.org
Twitter - http://twitter.com/robschertzer
or http://iguy.tv/twitter
Blog - http://wholelottarob.com
or http://iguy.tv/blog
Facebook - http://facebook.com/talkingaboutglaucoma
Office website - http://westcoastglaucoma.com
or http://iguy.tv/office
Theme music “Middle East Gold” ©Daniel Schertzer 2010 and published by Les Prods DOSWA Enr
© 2019 DOSWA Prods Enr/Robert M Schertzer MD. MEd, FRCSC
—————————————————————————
Today’s guest:
Richard A. Lewis, MD
Sacramento Eye Consultants
1515 River Park Drive, Suite 100, Sacramento, CA 95815
Tel: 1-916-649-1515
rlewiseyemd@yahoo.com
https://www.sacramentoeyeconsultants.com/sacramento/our-doctors/richard-a-lewis-md.htm
—————————————————————————
Intro:
Welcome back to Talking About Glaucoma, a podcast of indeterminate length and frequency. I’m your host Robert Schertzer, a Glaucoma Specialist from Vancouver, BC Canada. To help produce future shows more frequently, I will no longer include artwork and chapter markings. Hopefully this will get me back on track to publishing new episodes each month this coming year. As always, contact me at podcast@iguy.org if you have a glaucoma topic that you would like to discuss with me on a future episode.
In this episode, I talk with Murray Johnstone from Seattle about pulsatile flow through the Trabecular Meshwork and collector channels. We discuss the imaging improvements over the years that have made this possible including the latest phase-based OCT scans that result in nanometre resolution instead of the micrometre resolution of spectral domain scans that most of us are using in clinical practice.
Show Notes:
This topic spans decades of work that began prior to his fellowship and resumed around the year 2000 as the imaging technology began to become available to prove the theory. Aqueous outflow drugs increase the outflow pulsatility, not just flow. Goldmann thought the TM was rigid preventing he and Asher from being able to explain the pulsatile nature of the flow. The ocular pulse drives movement of the TM, which is not rigid. The drugs that improve outflow, do so by altering the blood flow to achieve their effect. This is literally a stroke volume.
The theoretical sensitivity to motion is in picometer with the newer phase-based OCTs, that of the movement of electrons in an atom, though practically we achieve nanometer resolution. This is sensitivity of motion of the TM walls, and not the resolution of an image.
How does this flow vary by location within the angle and from moment to moment? This is a live dynamic process. They have published numerous studies in both normal and abnormal outflow patients. Questions to answer include how this flow is altered by laser, meds, stent procedures? Does the act of doing the measurements also alter the flow? It is non-contact and non-invasive therefore should not be altering the flow but white-coat syndrome could have an influence. Perhaps in the future, we can instill a drop in the patient’s eye, measure the change in pulsatile flow, and be able to tell whether a particular medication will actually be effective.
We measure 12 seconds of 31 million seconds in a patient’s year when we check IOP several times per year. By determining pulsatile outflow we have the potential to achieve new diagnostic and treatment options for our patients. This is analogous to how cardiology is using imaging modalities in patient care.
Selected References for this episode related to pulsatile flow:
Johnstone MA, Grant WM. Microsurgery of Schlemm’s canal and the human aqueous outflow system. Am J Ophthalmol 1973;76:906-917.
Johnstone MA, Grant WG. Pressure-dependent changes in structures of the aqueous outflow system of human and monkey eyes. Am J Ophthalmol 1973;75:365-383.
Johnstone MA. Pressure-dependent changes in configuration of the endothelial tubules of Schlemm’s canal. Am J Ophthalmol 1974;78:630-638.
Johnstone MA. Pressure-dependent changes in nuclei and the process origins of the endothelial cells lining Schlemm’s canal.
Johnstone MA. The aqueous outflow system as a mechanical pump: evidence from examination of tissue and aqueous movement in human and non-human primates. J Glaucoma 2004;13:421-438.
Johnstone MA. A New Model Describes an Aqueous Outflow Pump and Explores Causes of Pump Failure in Glaucoma. In: Grehn H, Stamper R, eds. Essentials in Ophthalmology: Glaucoma II. Heidelberg: Springer, 2006
Johnstone MA. Aqueous Outflow: The case for a new model. Review of Ophthalmol 2007;14:79-84.
Schacknow P, Samples J, eds. Aqueous Veins. The Glaucoma Book. New York: Springer, 2010:65-78.
Johnstone M, Martin E, Jamil A. Pulsatile flow into the aqueous veins: manifestations in normal and glaucomatous eyes. Exp Eye Res 2011;92:318-327.
Li P, Reif R, Zhi Z, Martin E, Shen TT, Johnstone M, Wang RK. Phase-sensitive optical coherence tomography characterization of pulse-induced trabecular meshwork displacement in ex vivo nonhuman primate eyes. J Biomed Opt 2012;17:076026.
Li P, Shen TT, Johnstone M, Wang RK. Pulsatile motion of the trabecular meshwork in healthy human subjects quantified by phase-sensitive optical coherence tomography. Biomed Opt Express 2013;4:2051-2065
Johnstone MA, Saheb H, Ahmed II, Samuelson TW, Schieber AT, Toris CB. Effects of a Schlemm canal scaffold on collector channel ostia in human anterior segments. Exp Eye Res 2014;119:70-76.
Johnstone MA. Intraocular Pressure Regulation: Findings of Pulse-Dependent Trabecular Meshwork Motion Lead to Unifying Concepts of Intraocular Pressure Homeostasis. J Ocul Pharmacol Ther 2014;30:88-93.
Sun Y, Li P, Johnstone M, K W, T S. Pulsatile motion of trabecular meshwork in a patient with iris cyst by phase-sensitive optical coherence tomography. Quantitative Imaging in Medicine and Surgery 2015;5:171-173
Xin C, Wang RK, Song S, Shen T, Wen J, Martin E, Jiang Y, Padilla S, Johnstone M. Aqueous outflow regulation: Optical coherence tomography implicates pressure-dependent tissue motion. Exp Eye Res 2017;158:171-186.
Carreon T, van der Merwe E, Fellman RL, Johnstone M, Bhattacharya SK. Aqueous outflow - A continuum from trabecular meshwork to episcleral veins. Prog Retin Eye Res 2017;57:108-133.
Wang K, Johnstone MA, Xin C, Song S, Padilla S, Vranka JA, Acott TS, Zhou K, Schwaner SA, Wang RK, Sulchek T, Ethier CR. Estimating Human Trabecular Meshwork Stiffness by Numerical Modeling and Advanced OCT Imaging. Invest Ophthalmol Vis Sci 2017;58:4809-4817.
Xin C, Song S, Johnstone M, Wang N, Wang RK. Quantification of Pulse-Dependent Trabecular Meshwork Motion in Normal Humans Using Phase-Sensitive OCT. Invest Ophthalmol Vis Sci 2018;59:3675-3681.
Production information:
This episode was originally recorded March 2016 during the Annual Meeting of the American Glaucoma Society in Ft Lauderdale using two Shure SM58 microphones with a Marantz PMD661 digital recorder. Mixing and sound levelling were FINALLY completed in November 2018 on a MacBook Pro and an iMac using Hindenberg Journalist Pro software. There was a great deal of background noise requiring generous use of noise gate and compression filters, with reverb added back to bring the voices back to life. Narration was overdubbed using a Blue Yeti Microphone with Journalist Pro.
Opinions expressed in this podcast are those of the speakers and are not intended to be taken as the standard of care for glaucoma treatment. Please always weigh the complete clinical picture and involve patients with any decisions in their care.
Contact information:
Murray Johnstone, MD
Clinical Professor
University of Washington
Department of Ophthalmology
Seattle, WA USA
johnstone.murray@gmail.com
Robert M Schertzer, MD, MEd, FRCSC
podcast@iguy.org
Twitter - http://twitter.com/robschertzer
or http://iguy.tv/twitter
Blog - http://wholelottarob.com
or http://iguy.tv/blog
Facebook - http://facebook.com/talkingaboutglaucoma
Facebook glaucoma support group - https://www.facebook.com/groups/glaucomapatientgroup/
or http://iguy.tv/patientsupport
Office website - http://westcoastglaucoma.com
or http://iguy.tv/office
Theme music “Middle East Gold” ©Daniel Schertzer 2010 and published by Les Prods DOSWA Enr
© 2018 DOSWA Prods Enr/Robert M Schertzer MD. MEd, FRCSC
Closing remarks:
That’s our show for today. Thanks for your patience as I slowly post new episodes including a talk about the new glaucoma drug Rhopressa. Please rate this show on iTunes as this is the best way for other people to find the show.
You can subscribe using iTunes, PocketCasts, GooglePlay, Stitcher or wherever fine podcasts are found, and new episodes will appear in your podcast player as they come out. Please tell your friends and colleagues about the show.
Drop me a line at podcast@iguy.org with your comments, visit WholeLottaRob.com, WestCoastGlaucoma.com, or follow me on twitter @robschertzer. Links to all of these are in the show notes. Remember to keep fighting glaucoma by early detection so that nobody loses vision from this group of diseases.
In this episode, I’m talking with Ron Fellman from Glaucoma Associates of Texas about the Fellman Fluid Wave and its clinical implications in glaucoma surgery.
Episode Chapters:
Intro: Ron Fellman
Glaucoma Associates of Texas
Fluid Wave: what it isRelated strictly to conventional outflow
Evidence of patency of this system
When unroofing Schlemm’s canal a decade ago when viscocanalostomy was being popularized, injecting BSS you could see the outflow pathways
At times there would be no flow into the adjacent veins
Was I in the wrong spot?
Five years ago during Trabectome, wondered if the outflow could be visualized
Reduced the Episcleral Venous Pressure by putting patient into some raverse Trandelenberg and raised the bottle height to its highest
You don’t see this during normal phacoemulsification because usually you are forcing the Schlemm’s canal closed
How does the fluid get to the episclera?
In Trabectome, adjacent to the tip, can see segmental fluid outflow if focus at the limbus; first let foot off the foot-pedal to drop the eye pressure and look for blood to reflux in to AC, then floor the pedal and if there’s a connection through to the collector channel, then the fluid gets through the episclera via deep venous plex, mid venous plexus and then to the episcleral venous plexus super highway
Blanching is occurring as all the blood runs out of the tissue
Improve outflow where there isn’t or optimize existing flow?
Aqueous wants to go out the path of least resistance
If you see a blanching it means the deep and mid venous plexus are both open and this is where the trabectome will work the best
The blanching correlates best with the patients with the lowest IOP; averaging 11.9 on 1 med vs 19 on 3 meds
Zero re-op on those with good flow vs 36% in patients with a poor wave seen intra-operatively
However we still don’t have a way to modulate wound healing with a trabectome; so can still get granulation tissue that ruins the surgery
Would fluid wave work for other MIGS procedures?
With circumferential sclerotomy see a near uniform fluid wave
With an iStent if you hit the right spot, usually won’t see more than 1 or 2 clock hours of a fluid wave; and this would only be seen AFTER the iStent is in place so you can’t do this BEFORE putting in the iStent
What’s the outcome marker for MIGS surgery? With Trab, its bleb formulation; with MIGS don’t see something when the case ends
Reference:
Episcleral Venous Fluid Wave: Intraoperative Evidence for Patency of the Conventional Outflow System
Fellman, Ronald L. MD; Grover, Davinder S. MD, MPH
Journal of Glaucoma: August 2014 - Volume 23 - Issue 6 - p 347–350
Production information:
This episode was originally recorded March 2016 during the Annual Meeting of the American Glaucoma Society in Ft Lauderdale using two Shure SM58 microphones with a Marantz PMD661 digital recorder. Mixing and sound levelling were FINALLY completed in January 2018 on an iMac using Hindenberg Journalist Pro software. Narration was overdubbed using a Blue Yeti Microphone with Journalist Pro.
Opinions expressed in this podcast are those of the speakers and are not intended to be taken as the standard of care for glaucoma treatment. Please always weigh the complete clinical picture and involve patients with any decisions in their care.
Ronald L. Fellman, MD
Glaucoma Associates of Texas
Dallas office: 214-360-0000
Plano office: 972-612-9522
Fort Worth Office 817-923-2000
rfellman@aol.com
http://glaucomaassociates.com/glaucoma-specialists/ronald-l-fellman-md/
Robert M Schertzer, MD, MEd, FRCSC
podcast@iguy.org
Twitter - http://twitter.com/robschertzer
or http://iguy.tv/twitter
Blog - http://wholelottarob.com
or http://iguy.tv/blog
Facebook - http://facebook.com/talkingaboutglaucoma
Glaucoma Patient Group (support group) - https://www.facebook.com/groups/glaucomapatientgroup/
or http://iguy.tv/patientsupport
I am pleased to announce that I am returning to Vancouver, BC. Follow my website for the latest news and for Eye Facts for patients to learn more about glaucoma. http://westcoastglaucoma.com or http://iguy.tv/office
Theme music "Middle East Gold" ©Daniel Schertzer 2010 and published by Les Prods DOSWA Enr
© 2018 DOSWA Prods Enr/Robert M Schertzer MD. MEd, FRCSC
Future episodes include a long discussion with Murray Johnstone and a talk about the new glaucoma drug Rhopressa.
If you subscribe via iTunes, PocketCasts, GooglePlay, Stitcher or wherever fine podcasts are found, you will get the new episodes as they come out. If you like the show, please leave a rating on iTunes as this is the best way for others to find it and tell your friends about the show.
Drop me a line at podcast@iguy.org with your comments, visit WholeLottaRob.com, WestCoastGlaucoma.com, or follow me on twitter @robschertzer. Links to all of these are in the show notes. Remember to keep fighting glaucoma by early detection so that nobody loses vision from this group of diseases.
I sat down with Chris Johsnon at a recent American Glaucoma Society meeting to discuss some of my pet peeves about visual field testing and what lies on the horizon. Chris is Professor of Ophthalmology and Visual Sciences at the University of Iowa and a world renown Perimetry expert.
In this episode, Tom Harbin, from Eye Consultants of Atlanta, and I discuss ethical issues in the medical treatment of glaucoma. This includes generic vs brand name drugs, the need to shop around for the best price, and looking out for talks from so-called Key Opinion Leaders.
In this episode, I talk with Tracy Wright, now based at Kaiser Permanente in Washington DC. He was at the Bascom Palmer Eye Institute at the University of Miami when we recorded this conversation. The implications immediately effected how I look at visual fields in my patients but I have yet to see further studies that support what we discussed, namely that visual fields continue to progress for a long time even once the stimulus that led to the initial glaucoma damage has been removed, likely due to apoptosis. The findings you are about to here may be shocking. Please write to me with your comments. -------------------------------------------------- Production information: This episode was recorded live in March 2014 during the Annual Meeting of the American Glaucoma Society in Coronado, CA, using two Shure SM58 microphones with a Marantz PMD661 digital recorder. Mixing and sound levelling were FINALLY performed in January 2017 on a MacBook Pro using Levelator, and Hindenberg Journalist Pro software. Narration was overdubbed using a Heil PR40 Microphone with Journalist Pro. Opinions expressed in this podcast are those of the speakers and are not intended to be taken as the standard of care for glaucoma treatment. Please always weigh the complete clinical picture and involve patients with any decisions in their care. -------------------------------------------------- Robert M Schertzer, MD, MEd, FRCSC podcast@iguy.org Twitter - http://twitter.com/robschertzer or http://iguy.tv/twitter Blog - http://wholelottarob.com or http://iguy.tv/blog Although I closed down the West Coast Glaucoma Center after moving to the east coast in the Fall of 2013, the website is still alive as a resource for eye information at http://westcoastglaucoma.com or http://iguy.tv/office Theme music "Middle East Gold" ©Daniel Schertzer 2010 and published by Les Prods DOSWA Enr © 2017 DOSWA Prods Enr/Robert M Schertzer MD. MEd, FRCSC
In this episode, I talk with Nelson Winkler (a medical student at the time) and Cheryl Khanna (Glaucoma attending) at The Mayo Clinic, who analyzed the outcomes of their team based model for Glaucoma care. This physician- led model began in 2008 and has Ophthalmologists working together with Optometrists to deliver glaucoma care. With specific definitions for progression of the disease, patients are referred back to Ophthalmology at critical points or every two years if stable. This model was born out of necessity as they have just two glaucoma sub-specialists to care for a large patient population. It has allowed better allocation of resources so that patients who really need the glaucoma subspecialty care are not over-loaded with patients who are clearly stable.
[This is the .mp3 un-enhanced version of this podcast. The AAC .m4a version has chapter markers and artwork embedded in the podcast to enhance the experience on devices/apps that support this, which includes most podcasting apps on iOS and Android devices. It is the preferred version for experiencing this podcast.] In this episode, I talk with Suman Thapa about delivering glaucoma care in Nepal. This conversation took place long before the two massive earthquakes in 2015. I am happy to see that Suman is back at work caring for patients.
[This is the .mp3 un-enhanced version of this podcast. The AAC .m4a version has chapter markers and artwork embedded in the podcast to enhance the experience on devices/apps that support this, which includes most podcasting apps on iOS and Android devices. It is the preferred version for experiencing this podcast.] In this episode, Tom Samuelson and I discuss trabecular bypass procedures including the currently available & two future models of the iStent, and the Ivantis Hydrus Microstent. There is a tendency for doctors to prescribe third and fourth glaucoma medications even though it is well known that there is such a diminishing return after two medications. These ab-interno devices can serve as a glaucoma-lite procedure, the next step after two medications for those reluctant to proceed with a potentially more effective but more risky trabeculectomy. The use of multiple iStents, next generation devices, or targeting delivery to visualized collector ducts should lead to improvements in ab-interno trabecular bypass procedures in the years ahead.
In this episode, I talk with Florent Aptel, a glaucoma specialist in Grenoble, France, about his work in developing a modern day hi frequency ultrasound as a treatment for glaucoma in its early stages. Their group has developed a device that selectively focuses the energy on the ciliary body without collateral damage that offers hope as a future treatment modality.
In this episode, Dr Blumenthal and I discuss the not so obvious technique of peripheral laser iridotomy, emphasizing the shift away from the 12 o'clock position to a temporal location for most patients. We discuss the rationale for this shift, that includes the dramatic reduction in photopsias, as well as some tips and tricks in performing this technique.
In this episode, Dr Berlin and I discuss the elusive quest to have the Excimer Laser Trabeculostomy (ELT) that he pioneered gain traction after 30 years of development. (See the enhanced AAC version of this same episode for a version with chapter markers and images; not compatible on all devices but ideal version for iOS or computers.)
In this episode, Dr Solish and I discuss the art of “needling” a filtering bleb, or as he likes to call it, a Slit Lamp Revision (SLR), to resuscitate its function. Beginning with the history of when he first thought of the idea as a resident and it was shot down and how this evolved to using antimetabolites in conjunction with the needling in order to discourage fibroblasts from forming more scar tissue from the procedure. You might be surprised to learn what types of blebs are more likely to improve with Slit Lamp Revision! (See the enhanced version of this podcast for chapter markers and images.)
In this episode, Dr Krishna and I discuss the Eye HandBook app that he and partner Dr Ken Lord developed. This app, available for both iOS and Android devices, has been a huge success. How can you disagree when the price is FREE and it is loaded with useful information for eye care professionals? At the time of this recording in March 2011 the Android version had yet to be released but it has since been released…see links in the show notes for downloading the iPhone or Android versions.
In this episode, Dr Sarkisian and I discuass his use of Ologen branded collagen matrix in attempts to improve the success of glaucoma surgery. This novel modification has yet to gain widespread support and would still be considered experimental at the time of this recording.
In this episode, Dr De Moraes and I discuss risk factors for visual field progression in patients already diagnosed with and being treated for glaucoma. Dr De Moraes’ group found that patients with established glaucoma were more likely to progress when peak IOP was 18 mm Hg (millimeters of mercury) or higher. Other risk factors included thinning of the cornea, presence of disc hemorrhage in the retina of the eye, and atrophy in part of the eye.
In this episode, Dr Ehrlich and I discuss baseline corneal hysteresis and its relationship with the amount of IOP reduction in prostaglandin treatment. Josh Ehrlich is a fourth year medical student at the Weill Cornell Medical College in New York City. He begins his Ophthalmology residency July 2012 at the Wills Eye Institute.
In this episode, Dr Dale Heuer and I discuss the latest glaucoma surgical techniques and devices in search of solid evidence for their safety and effecacy. Trabeculectomy is the operation that we love to hate so we are always looking for something better. In some countries, new devices just require proving safety without having to show efficacy whereas in other countries both must be proven.
In this episode, Dr Nicolela and I discuss the risk factors for the development of glaucoma. This includes talking about the difference between risk factors for developing disease vs those for disease to progress. Much of our current knowledge is based on information from clilnical trials and population studies over the past decade. Bear in mind that still intraocular pressure remains as the single most important modifiable risk factor, even in normal tension glaucoma patients.
In this episode, Mr Foster and I discuss angle closure glaucoma focusing on epidemiology, mechanism and treatment (iridotomy and cataract extraction.)
In this episode, Drs Schuman, Burgoyne and I discuss optic nerve and nerve fiber layer iimaging in glaucoma. To clarify the different modalities, the Confocal Scanning Laser Ophthalmoscope (CSLO) has been popularized as the Heidelberg Engineering device, current version being the HRT 3; the Scanning Laser Polarimeter is the GDx machine, and; the original Optical Coherence Tomography unit and its next 2 generations were popularized by Zeiss and use Time Domain scanning whereas the latest technology uses Spectral Domain technology to achieve much higher resolution with the Spectralis OCT made by Heidelberg Engineering.
In this episode, Dr Damji and I discuss the use of Selective Laser Trabeculoplasty (SLT) in treating patients with open angle glaucoma. The conversation includes a comparison of this to Argon Laser Trabeculoplasty (ALT), the step-wise approach to treating patients with glaucoma and where the SLT might fit it. We also cover the burning question of the repeatability of this treatment modality as well as its contraindications.
In this episode, Dr Hom and I discuss things to consider in purchasing a Visual Field machine for your practice. We look at the choice based on the scope of your practice, networking, and sharing your data with colleagues. (See AAC version for complete show notes.)
In this episode, Cindy Hutnik and I discuss Central Corneal Thickness and how we use it as part of assessing patients with glaucoma.
In this second part of a two part conversation, we discuss the risk factors for progression in Normal Tension Glaucoma as determined by the Normal Tension Glaucoma Study.
Talking with Stephen Drance in part 1 of 2 about the Collaborative Normal Tension Glaucoma studies: how IOP effects NTG and the natural history of the disease.
A talk with Mark Lesk on systemic vascular endothelial dysfunction and how this pertains clinically to glaucoma. The balance between vasodilation from nitric oxide and vasoconstriction from endothelin-1.
A talk with Michael Coote on the GONE project to help ophthalmologists improve their skills in clinical assessment of the optic nerve.
A talk with Gustavo de Moraes on the predictive value of the presence of scotomas in both hemifields in patients with glaucoma.